The UK cell-therapy company Adaptimmune Ltd has entered a collaboration with GlaxoSmithKline Plc to advance the development of an autologous T-cell receptor product for patients with a variety of cancers. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
